Ono Pharmaceutical Co., Ltd. (OPHLY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ono Pharmaceutical Co., Ltd. (OPHLY) trades at $4.99 with AI Score 54/100 (Grade B). Ono Pharmaceutical Co. , Ltd. Market cap: $7.03B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for OPHLY: OPHLY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OPHLY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
OPHLY: 3/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Ono Pharmaceutical Co., Ltd. (OPHLY) Healthcare & Pipeline Overview
Ono Pharmaceutical Co., Ltd. is a long-established Japanese pharmaceutical firm, founded in 1717, specializing in the global development, manufacturing, and sale of innovative pharmaceuticals and diagnostic reagents. The company maintains a diversified product portfolio across oncology, diabetes, and neurological disorders, supported by an active R&D pipeline.
What Is the Investment Thesis for OPHLY?
Ono Pharmaceutical Co., Ltd. presents a research profile characterized by a robust and diversified product portfolio, particularly strong in oncology with key assets like OPDIVO and KYPROLIS, alongside significant offerings in diabetes and neurological disorders. The company's financial health is evidenced by a substantial market capitalization of $7.03B, a strong gross margin of 72.5%, and a profit margin of 13.5%, indicating efficient operations and profitability. A P/E ratio of 15.3 suggests a reasonable valuation within the pharmaceutical sector. Key growth catalysts include the successful advancement and commercialization of its extensive R&D pipeline, which targets a wide array of conditions from various cancers to neurodegenerative diseases. Expansion of existing drug indications and deeper penetration into global markets also represent significant opportunities. The company's dividend yield of 3.53% offers income potential, while a low beta of 0.11 suggests relative stability compared to the broader market. However, potential risks include the inherent uncertainties of drug development, intense competition, regulatory hurdles, and the eventual patent expirations of its blockbuster drugs.
Based on FMP financials and quantitative analysis
OPHLY Key Highlights
- Market Capitalization: $7.08 billion, reflecting its substantial presence in the global pharmaceutical sector.
- Profitability: A strong Gross Margin of 72.5% and a Profit Margin of 13.5% indicate efficient operations and effective cost management.
- Valuation: A P/E ratio of 15.3 suggests a reasonable valuation relative to earnings within the pharmaceutical industry.
- Shareholder Returns: Offers a Dividend Yield of 3.53%, providing income to investors.
- Market Stability: A Beta of 0.11 indicates significantly lower volatility compared to the broader market, suggesting relative stability.
Who Are OPHLY's Competitors?
OPHLY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| KYKOF Kyowa Kirin Co., Ltd. | $14.20 | -1.56% | $7.43B | 57 |
| GZPHF Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.34 | +0.00% | $6.20B | 43 |
| HLUBF H. Lundbeck A/S | $5.50 | +0.00% | $5.84B | 54 |
| DSRLF DiaSorin S.p.A. | $84.10 | +13.27% | $4.16B | 52 |
| HKMPY Hikma Pharmaceuticals PLC | $41.03 | -0.49% | $4.32B | 45 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OPHLY's Key Strengths?
- Diversified product portfolio across critical therapeutic areas like oncology, diabetes, and neurological disorders.
- Strong R&D pipeline with numerous candidates targeting various diseases, indicating future growth potential.
- Established global presence and a long operational history since 1717, fostering experience and market trust.
- High gross margin of 72.5% and profit margin of 13.5%, indicating strong operational efficiency and profitability.
What Are OPHLY's Weaknesses?
- Potential reliance on a few key blockbuster drugs for a significant portion of revenue, creating concentration risk.
- Exposure to intense competition in the global pharmaceutical market, requiring continuous innovation.
- Regulatory hurdles and lengthy, costly approval processes for new drugs can delay market entry.
- Potential for patent expirations on existing successful products, leading to loss of market exclusivity and revenue decline.
What Could Drive OPHLY Stock Higher?
- Potential regulatory approvals for pipeline drugs across various oncology indications, including esophageal, urothelial carcinoma, Hodgkin's lymphoma, and hepatocellular carcinoma, which could significantly expand market reach.
- Continued global sales growth of key oncology drugs such as OPDIVO and KYPROLIS, driven by existing and newly approved indications.
- Expansion of existing drug indications into new patient populations or disease stages, maximizing the commercial potential of established assets.
- Progress in clinical trials for late-stage development candidates targeting neurodegenerative diseases like Alzheimer's and Parkinson's, representing significant unmet medical needs.
What Are the Key Risks for OPHLY?
- Clinical trial failures or delays for pipeline products, which could result in substantial R&D losses and impact future revenue streams.
- Intense competition from other pharmaceutical companies and generic manufacturers, leading to pricing pressures and market share erosion.
- Regulatory setbacks or increased scrutiny from health authorities in key markets, which could delay or prevent drug approvals.
- Patent expirations on key revenue-generating drugs, leading to loss of market exclusivity and a decline in sales due to generic competition.
- Adverse events or safety concerns emerging from post-market surveillance of approved drugs, potentially leading to product recalls or restricted use.
What Are the Growth Opportunities for OPHLY?
- Oncology Pipeline Expansion: The company's extensive development pipeline includes numerous candidates for various malignant tumors such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, and hepatocellular carcinoma. Success in clinical trials and subsequent regulatory approvals for these indications could significantly expand the market reach of existing drugs like OPDIVO or introduce new blockbuster therapies. The global oncology market is projected to reach over $300 billion by 2030, offering substantial growth potential for novel treatments.
- Diabetes and Metabolic Disorders: Ono Pharmaceutical offers GLACTIV and FORXIGA for type 2 diabetes. Continued research and development in this area, potentially leading to new formulations, combination therapies, or expanded indications for these drugs, could capture a larger share of the growing global diabetes market. With millions diagnosed annually, the demand for effective diabetes management solutions remains high, presenting a sustained revenue stream.
- Neurological Disease Treatments: The company's portfolio includes RIVASTACH for Alzheimer's disease and ONGENTYS for Parkinson's disease, alongside a pipeline for neurodegenerative conditions. As global populations age, the incidence of these diseases rises, creating a vast unmet medical need. Breakthroughs in these complex therapeutic areas, particularly for conditions like Alzheimer's, could unlock multi-billion dollar market opportunities over the next decade.
- Expansion of Existing Drug Indications: Leveraging established drugs like OPDIVO (for malignant tumors) by securing approvals for additional indications can significantly extend their patent life and market penetration without the full cost of developing a new molecular entity. This strategy allows Ono Pharmaceutical to maximize the value of its existing assets across a broader patient population, driving incremental revenue growth and market share in competitive therapeutic landscapes.
- International Market Penetration: While the company operates worldwide, there is always potential for deeper penetration into emerging markets or expansion into new geographic regions where specific therapeutic needs are underserved. Establishing stronger distribution networks and navigating local regulatory frameworks in high-growth economies could open up significant new revenue streams and diversify the company's global sales footprint over the long term.
What Opportunities Does OPHLY Have?
- Expansion into new geographic markets, particularly emerging economies with growing healthcare needs.
- Successful development and commercialization of pipeline products in high-demand areas like oncology and neurodegeneration.
- Strategic partnerships and collaborations to enhance R&D capabilities, share risks, and expand market reach.
- Leveraging existing drug indications for new therapeutic uses to extend product life cycles and patient populations.
What Threats Does OPHLY Face?
- Increased competition from generic drug manufacturers and other pharmaceutical companies developing similar therapies.
- Stringent and evolving global regulatory environments which can impact drug development and approval timelines.
- Unsuccessful clinical trials or failure to obtain regulatory approvals for pipeline drugs, leading to significant R&D losses.
- Pricing pressures from healthcare systems, governments, and insurance providers seeking to control drug costs.
What Are OPHLY's Competitive Advantages?
- Extensive research and development capabilities, leading to a robust pipeline of innovative developmental products.
- Strong patent protection for key blockbuster drugs like OPDIVO, providing market exclusivity and revenue stability.
- Established global distribution networks and deep regulatory expertise across multiple international markets.
- A long operational history since 1717, fostering significant brand recognition and trust within the pharmaceutical industry.
- Diversified product portfolio spanning multiple critical therapeutic areas, which mitigates reliance on any single drug or market segment.
What Does OPHLY Do?
Ono Pharmaceutical Co., Ltd., a venerable institution founded in 1717 and headquartered in Osaka, Japan, has evolved from its historical roots into a global pharmaceutical powerhouse. The company, along with its subsidiaries, is dedicated to the production, purchase, and worldwide sale of pharmaceuticals and diagnostic reagents. Its extensive product portfolio addresses a wide array of critical therapeutic areas, demonstrating a commitment to innovation and patient care. In oncology, Ono Pharmaceutical offers significant treatments such as OPDIVO intravenous infusions for malignant tumors, KYPROLIS for intravenous injection, and EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting. The company also provides DEMSER capsules for pheochromocytoma, alongside MEKTOVI, VELEXBRU, ADLUMIZ tablets, and BRAFTOVI capsules, all targeting various malignant tumors. Beyond oncology, Ono Pharmaceutical is a key player in metabolic disorders, offering GLACTIV and FORXIGA tablets for type 2 diabetes. Its cardiovascular and circulatory system treatments include ONOACT injections for tachyarrhythmia, OPALMON tablets for peripheral circulatory disorder, and CORALAN for chronic heart failure. For autoimmune and inflammatory conditions, ORENCIA injections are provided for rheumatoid arthritis, while bone health is addressed with RECALBON tablets for osteoporosis. The company also supports neurological health with RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other significant products include PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and JOYCLU intra-articular injection for joint function improvement. Ono Pharmaceutical maintains a robust and diverse development pipeline, with products in various stages of research for conditions such as esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. This broad therapeutic focus and continuous R&D effort underscore its position as a significant global pharmaceutical entity.
What Products and Services Does OPHLY Offer?
- Develops and manufactures a wide range of pharmaceutical products for global distribution.
- Produces diagnostic reagents used in medical testing and analysis worldwide.
- Sells pharmaceuticals across various therapeutic areas, including oncology, diabetes, and neurological disorders.
- Offers key oncology treatments such as OPDIVO intravenous infusions and KYPROLIS for malignant tumors.
- Provides drugs for metabolic conditions like GLACTIV and FORXIGA for type 2 diabetes.
- Supplies treatments for neurological diseases, including RIVASTACH for Alzheimer's and ONGENTYS for Parkinson's.
- Maintains an extensive research and development pipeline targeting numerous diseases from cancer to autoimmune disorders.
- Operates internationally, with its headquarters located in Osaka, Japan.
How Does OPHLY Make Money?
- Research, develop, and obtain regulatory approval for novel pharmaceutical compounds and diagnostic reagents.
- Manufacture and distribute patented drugs and diagnostic reagents to healthcare providers and patients globally.
- Generate revenue primarily through the sales of its diverse portfolio of prescription medications across multiple therapeutic areas.
- Engage in strategic partnerships and licensing agreements to enhance R&D capabilities, expand market reach, and co-promote products.
What Industry Does OPHLY Operate In?
Ono Pharmaceutical Co., Ltd. operates within the highly competitive and innovation-driven Drug Manufacturers - General industry, a critical segment of the broader Healthcare sector. The global pharmaceutical market is characterized by continuous demand driven by an aging population, rising prevalence of chronic diseases, and advancements in medical science. Ono Pharmaceutical holds a significant position, particularly with its strong presence in oncology, diabetes, and neurological disorders. The industry is defined by extensive research and development expenditures, stringent regulatory approval processes, and the constant threat of patent expirations and generic competition. Ono Pharmaceutical distinguishes itself through its long history, diversified product offerings, and a deep pipeline of developmental drugs, positioning it as an established player capable of addressing unmet medical needs globally. The company competes with both large multinational pharmaceutical corporations and specialized biopharmaceutical firms in various therapeutic areas.
Who Are OPHLY's Key Customers?
- Hospitals, clinics, and healthcare institutions globally.
- Healthcare professionals, including oncologists, endocrinologists, neurologists, and general practitioners.
- Patients suffering from various conditions such as cancer, diabetes, Alzheimer's, Parkinson's, and autoimmune diseases.
- Diagnostic laboratories utilizing their specialized reagents for medical testing.
Company Profile
Ono Pharmaceutical Co., Ltd. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Osaka, JP. The company is led by CEO Gyo Sagara. OPHLY has traded publicly since 2012.
How Ono Pharmaceutical Co., Ltd. Is Valued
Ono Pharmaceutical Co., Ltd. carries a market capitalization of $7.03B, placing it in the mid-cap category. Relative to its peer group, OPHLY's quantitative score of 54/100 is roughly in line with the peer average of 50/100.
ROE 9%Key Financial Metrics
Return on equity for Ono Pharmaceutical Co., Ltd. stands at 8.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.3%, showing how much profit it generates from its asset base. OPHLY trades at a trailing price-to-earnings ratio of 15.29, below the Healthcare sector average of ~23x. Its free cash flow yield is 12.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Ono Pharmaceutical Co., Ltd.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.88 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Ono Pharmaceutical Co., Ltd. revenue of about $513.39B for fiscal 2026, with EPS near $51.17. The estimate reflects 11 contributing analysts.
OPHLY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the ongoing growth of Ono Pharmaceutical.
- Community sentiment has shifted positively as recent drug trial results have shown promising efficacy, boosting investor optimism.
- Analysts have noted an increasing interest in Ono's pipeline, particularly in oncology, which is gaining traction in the market.
- Market perception has been bolstered by strategic partnerships that enhance Ono's research capabilities and expand its market reach.
Bear Case
- Despite recent positive sentiment, there are lingering concerns about regulatory hurdles that could delay product approvals, creating uncertainty for investors.
- Some community members express skepticism regarding the sustainability of Ono's growth, citing competition in the pharmaceutical sector as a potential threat.
- Recent fluctuations in market sentiment indicate that investors are cautious, reflecting broader economic concerns that could impact stock performance.
- There is a perception that Ono's current valuation may not fully reflect the inherent risks associated with drug development timelines and market entry.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
OPHLY Latest News
No recent news available for OPHLY.
OPHLY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OPHLY.
Price Targets
Wall Street price target analysis for OPHLY.
OPHLY MoonshotScore
What does this score mean?
The MoonshotScore rates OPHLY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gyo Sagara
Unknown
Unknown
Track Record: Unknown
Ono Pharmaceutical Co., Ltd. ADR Information Unsponsored
Ono Pharmaceutical Co., Ltd. trades as an American Depositary Receipt (ADR) Level 1, which allows U.S. investors to own shares of a foreign company without directly trading on its home stock exchange. These ADRs are typically traded on the U.S. over-the-counter (OTC) market. Each OPHLY ADR represents a specific number of shares of the underlying common stock, OPHL, which trades on the Tokyo Stock Exchange in Japan, facilitating easier access for American investors.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: OPHL
OPHLY OTC Market Information
Ono Pharmaceutical Co., Ltd. trades on the OTC Other tier of the OTC Markets Group, which is the lowest tier. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, OTC Other companies have minimal public disclosure requirements. This tier is for companies that do not meet the standards for OTCQX or OTCQB, or choose not to provide financial information to the public. This can result in less transparency compared to higher tiers or exchange-listed securities, as there are no mandated financial reporting standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lack of comprehensive public disclosure and financial reporting, making it difficult for investors to conduct thorough due diligence.
- Lower liquidity and wider bid-ask spreads compared to exchange-listed stocks, potentially leading to unfavorable transaction prices.
- Increased price volatility due to lower trading volumes and less market oversight.
- Limited analyst coverage and institutional interest, which can hinder price discovery and market efficiency.
- Higher susceptibility to manipulation and fraud due to less stringent regulatory requirements and oversight.
- Verify the company's business operations and product portfolio through official company websites and reputable financial news sources.
- Examine any available financial statements or annual reports, even if not SEC-mandated, to assess financial health and performance.
- Research the company's management team and their track record, looking for experience and transparency.
- Investigate any news or regulatory filings from the company's home country (Japan) for relevant information.
- Assess the market for its key products and the competitive landscape to understand its revenue potential.
- Evaluate the dividend history and sustainability, given the company's dividend yield.
- Consider the impact of currency exchange rates on the ADR's value and dividend payments.
- Long operating history since 1717, indicating established business operations and resilience.
- Substantial market capitalization of $7.03B, suggesting a significant and recognized entity.
- A diversified portfolio of globally recognized pharmaceutical products, including OPDIVO and KYPROLIS.
- Global operations and headquarters in Japan, a developed economy with robust regulatory frameworks.
- Consistent dividend yield of 3.53%, which often signals financial stability and commitment to shareholders.
Common Questions About OPHLY (Healthcare)
What are Ono Pharmaceutical Co., Ltd.'s primary therapeutic areas of focus?
Ono Pharmaceutical Co., Ltd. maintains a broad and diversified therapeutic focus, with significant strengths in oncology, metabolic disorders, and neurological diseases. In oncology, the company offers blockbuster drugs like OPDIVO and KYPROLIS for various malignant tumors, alongside treatments for chemotherapy-induced nausea and vomiting. For metabolic conditions, it provides GLACTIV and FORXIGA for type 2 diabetes. The company also addresses neurological health with RIVASTACH for Alzheimer's disease and ONGENTYS for Parkinson's disease. Additionally, Ono Pharmaceutical has products for cardiovascular disorders, autoimmune conditions, respiratory ailments, and osteoporosis, demonstrating a comprehensive approach to global health challenges.
How does Ono Pharmaceutical Co., Ltd. manage its extensive drug development pipeline?
Ono Pharmaceutical Co., Ltd. manages its extensive drug development pipeline through a rigorous, multi-stage research and development process aimed at identifying, developing, and commercializing innovative therapies. The company's pipeline is highly diversified, targeting a wide range of conditions from various cancers (e.g., esophageal, urothelial, Hodgkin's lymphoma) to neurodegenerative diseases, autoimmune disorders, and rare conditions. This strategy involves significant investment in preclinical research, followed by multiple phases of clinical trials to assess safety and efficacy. By pursuing numerous candidates across different therapeutic areas, Ono Pharmaceutical aims to mitigate the inherent risks of drug development and ensure a continuous stream of potential new products to address unmet medical needs globally.
What are the unique considerations for investors in Ono Pharmaceutical Co., Ltd. given its ADR and OTC listing?
Investing in Ono Pharmaceutical Co., Ltd. through its OPHLY ADR on the OTC market presents several unique considerations. As a Level I ADR, it trades on the OTC Other tier, implying less stringent public disclosure requirements compared to major exchanges, which can make due diligence more challenging. The OTC listing also typically results in lower liquidity and wider bid-ask spreads, potentially affecting transaction costs and the ease of trading. Furthermore, as a Japanese company, ADR holders are exposed to currency risk from fluctuations between the Japanese Yen and the U.S. Dollar, impacting both the ADR's value and dividend payments. Japanese withholding taxes on dividends are also a factor, though U.S. investors may be eligible for foreign tax credits.
What are the key factors to evaluate for OPHLY?
Ono Pharmaceutical Co., Ltd. (OPHLY) holds an AI score of 54/100 (moderate). P/E: 15.3x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does OPHLY data refresh on this page?
OPHLY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OPHLY's recent stock price performance?
Ono Pharmaceutical Co., Ltd. (OPHLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across critical therapeutic areas like oncology, diabetes, and neurological disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OPHLY overvalued or undervalued right now?
Ono Pharmaceutical Co., Ltd. (OPHLY) trades at 15.3x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OPHLY?
Before investing in Ono Pharmaceutical Co., Ltd. (OPHLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based solely on provided source data.
- CEO's title, background, track record, and tenure are not available in the provided data and are marked as 'Unknown' or 'null'.